Nyxoah raises USD 95 million in share sale to fund US Genio rollout

Nyxoah SA

Nyxoah SA

NYXH

0.00
  • Nyxoah priced a $95 million share offering, lifting total new funding to $110 million when a $15 million second tranche from its European Investment Bank loan is received by late June 2026.
  • The proceeds are set to accelerate the US commercial rollout of its Genio obstructive sleep apnea therapy.
  • The company cited momentum from its first two US commercial quarters, supported by a 40-person US salesforce.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nyxoah SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606101630OMX_____CNEWS_FR_GNW1001187075_fr) on June 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.